Twist生物科学的收入在DNA合成和AI治疗的驱动下,在更新的全年指导及改善的利润率下,Yoy收入增长了17%,在Q1 2026年,达到103.7百万美元。 Twist Bioscience's revenue rose 17% YoY to $103.7M in Q1 2026, driven by DNA synthesis and AI therapeutics, with updated full-year guidance and improved margins.

Twist生物科学报告说,2026年第一季度的收入为1.037亿美元,比上一年增加17%,增长的第12个连续季度,其驱动因素是DNA合成和AI促成的治疗发现方面的强劲需求。 Twist Bioscience reported first-quarter 2026 revenue of $103.7 million, a 17% increase year-over-year and its 12th straight quarter of growth, driven by strong demand in DNA synthesis and AI-enabled therapeutic discovery. 该公司将其全年收入指导提高到4.35 - 4.4亿美元,将其经调整的EBITDA损失缩小到1 340万美元,并将总利润率提高至52.0%。 The company raised its full-year revenue guidance to $435–440 million, narrowed its adjusted EBITDA loss to $13.4 million, and improved gross margin to 52.0%. NGS申请收入逐年增长18%,与AI相关的订单在2025财政年度超过了2 500万美元。 NGS applications revenue grew 18% year-over-year, and AI-related orders exceeded $25 million in fiscal 2025. Twist重申其目标,即到2026年实现经调整的EBITDA突破平衡(Q4 2026),并期望现有诊断伙伴的增长,并计划今后扩大新的伙伴关系。 Twist reiterated its goal to achieve adjusted EBITDA break-even by Q4 2026 and expects growth from existing diagnostic partners, with new partnerships planned for future expansion.